Insmed Incorporated (INSM) Stock Analysis
A live, multi-source view of Insmed Incorporated (INSM): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension.
Sector: Healthcare · Industry: Biotechnology · United States · 1,664 employees · insmed.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Insmed Incorporated (INSM) had a market capitalization of $27.58B (forward 157.4) and a beta of 0.82; the shares traded in a 52-week range of $90.39 – $212.75 (-13.9% over the year).
- Market cap
- $27.58B
- Enterprise value
- $27.24B
- Forward P/E
- 157.4
- PEG ratio
- 1.09
- Price / book
- 36.39
- EPS (trailing)
- $-4.10
- EPS (forward)
- $0.80
- Payout ratio
- 0.0%
- 52-week range
- $90.39 – $212.75
- 52-week change
- -13.9%
- Beta
- 0.82
- Average volume
- 3.3M
- Shares outstanding
- 218.4M
- Short % of float
- 5.62%
- Profit margin
- -76.9%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Insmed Incorporated (INSM) last closed at $126.29 (the last completed close before that scan).
Technicals at the scan: RSI 58 (neutral territory), price +0.1% versus its 20-day average, 20-day versus 50-day average spread +9.0%, MACD histogram -0.53.
Sentiment inputs: 80% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 80/100.
Next scheduled company event: in 51 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 1 sell of INSM; corporate insiders filed 0 buys and 2 sells (2 distinct filers, latest disclosure 2026-07-24). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: William Lewis (0B/2S), Josh Gottheimer (0B/1S). Who is trading what
RapidTradeView pick record
INSM has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Insmed Incorporated (INSM) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell INSM.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.